HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients

American Journal of Kidney Diseases

Volumn 45, Issue 1, 2005, Pages 119-126

  Mason, Nancy A ^a,b   Bailie, George R ^b,d,e   Satayathum, Sudtida ^c   Bragg Gresham, Jennifer L ^c   Akiba, Takashi ^f   Akizawa, Tadao ^g   Combe, Christian ⁱ   Rayner, Hugh C ^j   Saito, Akira ^h   Gillespie, Brenda W ^a   Young, Eric W ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Nephrology Pharmacy Associates   (United States)

^c Univ Ren Res and Educ Assoc   (United States)

^d RENAL RESEARCH INSTITUTE   (United States)

^e ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^f TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^g WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^h TOKAI UNIVERSITY   (Japan)

ⁱ HÔPITAL SAINT ANDRÉ   (France)

^j BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

more..

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A (HMG CoA) reductase inhibitors; Cardiovascular disease; cholesterol; hemodialysis (HD); hyperlipidemia; statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; COVARIANCE; FEMALE; HEMODIALYSIS; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PRESCRIPTION; PROSPECTIVE STUDY; RISK ASSESSMENT;

COMORBIDITY; FEMALE; FRANCE; GERMANY; GREAT BRITAIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ITALY; JAPAN; KIDNEY FAILURE, CHRONIC; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OBSERVATION; PRESCRIPTIONS, DRUG; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK ASSESSMENT; SPAIN; UNITED STATES;

EID: 19944366583     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2004.09.025     Document Type: Article

References (26)

1. US Renal Data System USRDS 2002 Annual Data Report 2002 The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
3. F. Locatelli, J. Bommer, G.M. London Cardiovascular disease determinants in chronic renal failure Clinical approach and treatment Nephrol Dial Transplant 16 2001 459 468
4. C. Wanner, V. Krane, T. Metzger, T. Quaschning Lipid changes and statins in chronic renal insufficiency and dialysis J Nephrol 14 suppl 4 2001 S76 S80
5. National Kidney Foundation K/DOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease Am J Kidney Dis 41 suppl 3 2003 S1 S92
6. E.W. Young, D.A. Goodkin, D.L. Mapes The Dialysis Outcomes and Practice Patterns Study (DOPPS) An international hemodialysis study Kidney Int Suppl 74 2000 S74 S81
7. D.A. Goodkin, D.L. Mapes, P.J. Held The Dialysis Outcomes and Practice Patterns Study (DOPPS) How can we improve the care of hemodialysis patients? Semin Dial 14 2001 157 159
8. J.P. Klein, M.L. Moeschberger Survival Analysis Techniques for Censored and Truncated Data 1997 Springer New York, NY 417
9. S.L. Seliger, N.S. Weiss, D.L. Gillen HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients Kidney Int 61 2002 297 304
10. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease The Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
11. F.M. Sacks, M.A. Pfeffer, L.A. Moye The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1996 1001 1009
12. J. Shepherd, S.M. Cobbe, I. Ford Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N Engl J Med 333 1995 1301 1307
13. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals A randomised placebo-controlled trial Lancet 360 2002 7 22
14. M. Tonelli, F.M. Sacks, B. Kiberd Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency Ann Intern Med 138 2003 98 104
15. P.S. Sever, B. Dahløf, N.R. Poulter Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) A multicentre randomised controlled trial Lancet 361 2003 1149 1158
16. H. Holdaas, B. Fellström, A.G. Jardine Effect of fluvastatin on cardiac outcomes in renal transplant recipients A multicentre, randomized, placebo controlled trial Lancet 361 2003 2024 2031
17. Y. Liu, J. Coresh, J.A. Eustace Association between cholesterol level and mortality in dialysis patients JAMA 291 2004 451 459
18. S.L. Seliger, C.O. Stehman-Breen Are HMG-CoA reductase inhibitors underutilized in dialysis patients? Semin Dial 16 2003 179 185
19. J.C. Longenecker, J. Coresh, N.R. Powe Traditional cardiovascular disease risk factors in dialysis patients compared with the general population The CHOICE study J Am Soc Nephrol 13 2002 1918 1927
20. K. Harris, M. Thomas, C. Short, R. Moore Assessment of the efficiency of treatment of dyslipidaemia in renal outpatients J Nephrol 15 2002 263 269
21. D. Saltissi, C. Morgan, R.J. Rigby, J. Westhuyzen Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis Am J Kidney Dis 39 2002 283 290
22. J.W. Chang, W.S. Yang, W.K. Min Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients Am J Kidney Dis 39 2002 1213 1217
23. K.P. Harris, D.C. Wheeler, C.C. Chong Atorvastatin in CAPD Study Investigators A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD Kidney Int 61 2002 1469 1474
24. B. Fellstrom, H. Holdaas, A. Jardine Why do we need a statin trial in hemodialysis patients? Kidney Int Suppl 84 2003 S204 S206
25. C. Baigent, M. Landry Study of Heart and Renal Protection (SHARP) Kidney Int Suppl 84 2003 S207 S210
26. C. Wanner, V. Krane, G. Ruf Die Deutsche Diabetes Dialyse Studie Investigators Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis Kidney Int 71 Suppl 1999 S222 S226